BP-897

BP-897 is a dopamine D₃ receptor partial agonist.¹ It selectively binds to the dopamine D₃ over the D₂, D₁, and D₄ receptors (K_is = 0.92, 61, 3,000, and 300 nM, respectively, for the recombinant human receptors). It is also selective over α₁- and α₂-adrenergic receptors (K_is = 60 and 83 nM, respectively) and the serotonin (5-HT) receptor subtypes 5-HT_1A and 5-HT₇ (K_is = 84 and 345 nM, respectively), as well as muscarinic, histamine, and opioid receptors (K_is = >1 µM for all). BP-897 inhibits cAMP accumulation induced by forskolin (EC₅₀ = 1 nM) and increases mitogenesis in NG 108-15 cells with a maximum efficacy of 55%, an effect that can be blocked by the dopamine D₃ receptor antagonist nafadotride. It also acts as a dopamine D₃ receptor antagonist, failing to increase [³⁵S]GTPγS binding to CHO cell membranes expressing the recombinant human D₃ receptor and inhibiting the effect of dopamine in the same assay (IC₅₀ = 416.87 nM).² BP-897 (0.5 and 1 mg/kg) reduces cocaine-seeking behavior, but has no reinforcing properties itself, in rats trained to self-administer cocaine.¹

WARNING This product is not for human or veterinary use.

1. Pilla, M., Perachon, S., Sautel, F., et al. Selective inhibition of cocaine-seeking behaviour by a partial dopamine D₃ receptor agonist. Nature 400(6742), 371-375 (1999).

2. Wicke, K., and Garcia-Ladona, J. The dopamine D₃ receptor partial agonist, BP 897, is an antagonist at human dopamine D₃ receptors and at rat somatodendritic dopamine D₃ receptors. Eur. J. Pharmacol. 424(2), 85-90 (2001).